H-ISAC and Where to Monitor Medical Device Cybersecurity Threats in 2026

The FDA does not let manufacturers say "we monitor for threats" and stop there. Section 524B(b)(1) requires a written postmarket plan that names where you watch, how often, and who acts on what you find. Reviewers increasingly ask for that list by source, and a plan that only cites NVD draws deficiencies because NVD alone misses the sector-specific exploitation chatter that hits health delivery organizations first.

The Health Information Sharing and Analysis Center (H-ISAC) is the anchor most mature programs build around, but it is one feed in a stack. This guide walks through the authoritative sources, what each one actually delivers, and how to wire them into your SBOM and vulnerability management workflow without drowning the team.

Key Takeaways

• H-ISAC delivers sector-specific, TLP-coded threat intelligence and runs the Medical Device Security Council, the only working group focused on manufacturer-side concerns.
• CISA's KEV catalog and ICS advisories surface actively exploited vulnerabilities faster than NVD and are the FDA's de facto signal for what counts as an urgent postmarket risk.
• NVD and CVE.org are the baseline machine-readable feeds your SBOM monitoring tooling consumes, but they lag exploitation reality by days to weeks.
• MITRE ATT&CK for ICS and CAPEC give you the adversary technique vocabulary reviewers expect to see in threat models and postmarket plans.
• Upstream vendor PSIRTs (Linux kernel, OpenSSL, BusyBox, chipset vendors) are the only authoritative source for component vulnerabilities before they reach NVD.
• A defensible 524B(b)(1) plan names each source, the monitoring cadence, and the trigger criteria that move a finding into your CAPA or expedited update process.

Table of Contents

• Why does the FDA care which sources you monitor?
• What is H-ISAC and what does it deliver?
• What does CISA provide that H-ISAC does not?
• Where do NVD, CVE.org, and MITRE fit?
• Which vendor and community sources matter for medical devices?
• How should these feeds map to your 524B postmarket plan?
• How Blue Goat approaches threat intelligence integration
• FAQ

Why this matters

The FDA's February 3, 2026 final premarket cybersecurity guidance ties premarket approval to a credible postmarket monitoring plan, and Section 524B(b)(1) of the Federal Food, Drug, and Cosmetic Act makes that plan a statutory obligation for cyber devices. Reviewers want named sources, not "industry feeds." A 2024 CISA fact sheet on the healthcare and public health sector notes the sector is among the most-targeted critical infrastructure verticals, and CISA's Known Exploited Vulnerabilities catalog is the operational signal federal agencies use to prioritize remediation. AAMI TIR97 explicitly calls for documented threat intelligence inputs to postmarket security risk management, and IEC 81001-5-1 §9.4 ties continued monitoring to the secure development lifecycle. A submission that lists only NVD as the monitoring source ignores all of this and reads, to a reviewer, as a paper exercise.

What is H-ISAC and what does it deliver?

The Health Information Sharing and Analysis Center is the sector ISAC for healthcare, recognized under Presidential Policy Directive 21. Membership is paid and tiered, and the value is in what the public feeds do not show: pre-disclosure indicators, TLP:AMBER and TLP:RED briefings, peer-to-peer incident sharing, and the Medical Device Security Council (MDSC), a working group focused specifically on manufacturer obligations.

For device manufacturers, the high-leverage outputs are the Daily Cyber Headlines and Threat Bulletins, the monthly Hacking Healthcare report, and MDSC working sessions where peers discuss in-the-wild exploitation against medical equipment before CVEs are public. H-ISAC also operates a 24x7 Threat Operations Center that members can query directly.

[KEY REQUIREMENT] If your postmarket plan claims to monitor "industry threat sharing," reviewers expect a named ISAC. For healthcare devices, that is H-ISAC. Naming it, and documenting that you triage its bulletins on a defined cadence, is the cleanest way to satisfy the sharing-and-coordination expectation in the FDA's 2026 guidance.

What does CISA provide that H-ISAC does not?

CISA is the federal operational arm for critical infrastructure cybersecurity, and three of its feeds are non-negotiable for medical device monitoring.

The Known Exploited Vulnerabilities catalog lists CVEs with confirmed active exploitation in the wild. The FDA treats KEV listings as a strong indicator that a vulnerability warrants out-of-cycle patching under 524B(b)(2)(B). If a component in your SBOM appears in KEV, you have a clock running.

CISA's ICS Advisories (formerly ICS-CERT) are where the vast majority of medical device CVEs are formally disclosed, often co-authored with the FDA and the manufacturer. Subscribing to the ICS advisory feed catches device-specific disclosures that never appear in the general CISA bulletin.

CISA also publishes Binding Operational Directives and sector-specific alerts that, while not binding on manufacturers, telegraph what the federal government considers urgent and frequently foreshadow FDA Safety Communications.

Where do NVD, CVE.org, and MITRE fit?

These are the baseline machine-readable feeds that automated SBOM monitoring tooling (Dependency-Track, OWASP DC, commercial SCA) consumes.

Source	What it gives you	What it does not
NVD	CVSS scores, CPE matching, CWE mapping	Lags CVE publication; no exploitation signal
CVE.org	Authoritative CVE records as published by CNAs	No scoring, no exploitation context
MITRE ATT&CK for ICS	Adversary technique taxonomy reviewers expect in threat models	Not a vulnerability feed
MITRE CWE	Weakness taxonomy used in IEC 81001-5-1 traceability	Not exploitable findings
MITRE CAPEC	Attack pattern catalog used in threat enumeration	Not real-time

NVD is necessary but not sufficient. Treat it as the SBOM correlation feed and pair it with KEV for prioritization and H-ISAC for sector context.

Which vendor and community sources matter for medical devices?

The components in your SBOM are disclosed by their owners first and reach NVD second. If you only watch NVD, you are days or weeks behind.

• Linux kernel security mailing list and distribution PSIRTs (Red Hat, Debian, Yocto) for the OS layer
• OpenSSL Security Advisories and BusyBox project notices for ubiquitous embedded components
• Chipset and SoC vendor PSIRTs (NXP, STMicro, Qualcomm, Intel) for firmware-level disclosures
• Open Source Vulnerabilities (OSV.dev) for a normalized cross-ecosystem feed
• FDA Medical Device Safety Communications at fda.gov for device-specific alerts the agency issues directly
• MAUDE for adverse event reports that may indicate cyber-related malfunction patterns
• Your own Coordinated Vulnerability Disclosure intake — required under 524B(b)(1), and one of the highest-quality intelligence sources you will ever operate because the reports come pre-targeted to your product

See also: Medical Device Incident Response Plan: FDA Expectations 2026, FDA Section 524B Explained Subsection by Subsection: What Each Requirement Means in 2026, and CAPA and Medical Device Cybersecurity: Closing the Loop on Vulnerabilities and FDA Deficiencies.

[KEY REQUIREMENT] Map each component class in your SBOM to a named upstream source. "We watch upstream vendors" without enumeration is the most common 524B(b)(1) deficiency pattern we see.

How should these feeds map to your 524B postmarket plan?

A defensible plan has four columns for every source: what feed, who owns it, what cadence, and what triggers action. A minimal worked example:

Source              Owner          Cadence      Trigger
H-ISAC bulletins    Security PM    Daily        TLP:AMBER+ on device class
CISA KEV            SBOM tooling   Continuous   Any SBOM component listed
CISA ICS adv.       Security PM    Daily        Any advisory naming our class
NVD (via SCA)       SBOM tooling   Continuous   CVSS >= 7 on SBOM component
Vendor PSIRTs       Eng leads      Per release  Any advisory on shipped version
CVD intake          PSIRT          Real-time    Any valid report

Triggers should route to either your CAPA system, your expedited out-of-cycle update process under 524B(b)(2)(B), or your acknowledged risk register, with the routing decision documented per finding. Reviewers ask for evidence of the process, not the queue.

Talk to our team about a 524B postmarket plan review — we'll benchmark your current source list against what the FDA is currently flagging in deficiency letters.

How Blue Goat approaches threat intelligence integration

We build postmarket monitoring plans the way reviewers grade them: by source, cadence, and trigger. Our team holds CISSP and OSCP credentials, includes ex-military red team operators, and works exclusively on medical device cybersecurity. We map every component class in your SBOM to a named authoritative source, write the trigger logic into your QMSR procedures, and tie the routing into your CAPA system so a KEV listing or H-ISAC bulletin produces a documented decision, not an email thread.

Where clients lack H-ISAC membership, we help build the business case and document the interim compensating sources. Learn more at Postmarket SBOM and VEX Monitoring. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

What is H-ISAC and do medical device manufacturers need to join?

H-ISAC is the Health Information Sharing and Analysis Center, the federally-recognized ISAC for healthcare. Manufacturers are not required by statute to join, but the FDA's 2026 guidance points to ISAC participation as evidence of credible sharing and coordination, and H-ISAC's Medical Device Security Council is the only working group focused on manufacturer obligations.

Is CISA KEV the same as NVD?

No. NVD catalogs all CVEs with CVSS scores. KEV is a curated subset of vulnerabilities with confirmed in-the-wild exploitation. KEV is the prioritization signal; NVD is the baseline catalog. A vulnerability can sit at CVSS 6.5 in NVD and still warrant emergency patching if it lands in KEV.

Where are most medical device CVEs disclosed?

The majority of medical device CVEs are published through CISA's ICS Advisories feed, typically co-authored by CISA, the FDA, and the manufacturer. Subscribing to that specific feed catches device disclosures the general CISA bulletin omits.

Does monitoring NVD alone satisfy 524B(b)(1)?

No. NVD lags exploitation reality and provides no sector context. A plan that names only NVD reads as a paper exercise and routinely draws deficiencies. Add H-ISAC, CISA KEV, CISA ICS advisories, and upstream vendor PSIRTs at minimum.

How often should we review threat intelligence feeds?

Automated feeds (NVD via SCA, KEV) run continuously. Human-curated sources (H-ISAC bulletins, ICS advisories) should be triaged daily by a named owner. Monthly cadence is too slow and is a common deficiency pattern reviewers cite.

What is the role of vendor PSIRTs?

Upstream component owners disclose vulnerabilities to their security advisory channels before records reach NVD. For SBOM components like the Linux kernel, OpenSSL, or chipset firmware, the PSIRT is the authoritative first source and the only way to catch issues in time for an out-of-cycle update decision.

Ready to harden your postmarket monitoring?

Schedule a discovery session to map your SBOM to a named-source monitoring plan that holds up under FDA scrutiny. If we submit it and the FDA raises cybersecurity deficiencies, we resolve them at no additional cost.

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, and has built postmarket threat intelligence programs for manufacturers ranging from Class II wearables to Class III implantables. Read more about Christian.